MINNEAPOLIS, June 29, 2022 (GLOBE NEWSWIRE) — PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (“PetVivo”), an emerging biomedical device company focused on commercializing innovative medical devices and other therapies for equine and companion animal athletes, today announced that it has entered into a definitive exclusive distribution services agreement with MWI Animal Health, a leading distributor of animal health products and services and a subsidiary of AmerisourceBergen.
MWI will inventory, market and promote PetVivo’s veterinary medical device, Spryng™ with OsteoCushion™ technology, across the United States. Through its network of distribution centers in key markets nationwide, MWI can support efficient deliveries to communities nationwide.
“We are delighted with the commitment MWI has made to PetVivo in rolling out this new relationship which includes the distribution of our flagship product, Spryng. We view MWI as a strategic partner that will provide PetVivo with significant exposure and penetration to U.S. animal health market. This new relationship will benefit the industry, the veterinarian providing medical care, their patients and the pet owner,” said John Lai, president and CEO of PetVivo. .
PetVivo’s innovative product, Spryng with OsteoCushion Technology, is a veterinary medical device comprised of millions of micronized hydrogel matrices, which are derived from naturally occurring biocompatible components. OsteoCushion technology provides both natural joint support to augment and strengthen missing and/or damaged cartilage, as well as a natural scaffold to help treat tissue defects. These attributes provide an excellent solution for managing lameness and joint conditions, such as osteoarthritis, for pets in a simple in-clinic administration.
“We continue to see tremendous innovation in the animal health industry, including the emergence of new therapies and devices. We are working closely with the companies leading these efforts to ensure veterinarians nationwide have access to the latest products and services that can help pets live longer, healthier lives,” said Steve Shell, President. from MWI Animal Health. “We are excited to work with PetVivo to provide veterinarians with fast and reliable access to the company’s new medical device.”
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (NASDAQ: PETV & PETVW) is an emerging biomedical device company currently focused on manufacturing, marketing and licensing of innovative medical and therapeutic devices for companion animals. The Company’s strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient manner. A key part of this strategy is accelerating the revenue timeline for veterinary medical devices, which enter the market much earlier than more strictly regulated pharmaceuticals and biologics.
PetVivo has a pipeline of seventeen products for the treatment of animals and people. A portfolio of nineteen patents protects the Company’s biomaterials, products, production processes and methods of use. The Company’s lead product SPRYNG™ with OsteoCushion™ Technology, a veterinarian-administered intra-articular injection for the management of lameness and other joint conditions, including osteoarthritis, in dogs and horses, is currently available for sale.
For more information about PetVivo Holdings, Inc. and our breakthrough product, Spryng with OsteoCushion Technology, please contact [email protected] or visit https://petvivo.com/
John Lai, CEO PetVivo Holdings, Inc. Email: [email protected] (952) 405-6216
Forward-looking business statements:
The foregoing information may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including, without limitation, the Company’s proposed development and business timelines, and can be identified by the use of words such as “may”, “will”, “expect”, “project”, “estimate”, “anticipate”, “plan”, “believe”, “potential”, “should”, “continue” or negative versions of these words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements, including the potential listing of the Company’s common stock on Nasdaq, are based on currently available information of the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could affect significantly the current plans. Risks relating to the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2021 and in other periodic and routine reports filed with the Securities and Exchange Commission. . The Company is under no obligation to update or change its forward-looking statements, and expressly disclaims any such obligation, whether as a result of new information, future events or otherwise.